search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Image guided Pre-operative Accelerated partial Breast Irradiation (PAPBI): Defening radiotherapy sensivity.


- candidate number8716
- NTR NumberNTR2633
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR30-nov-2010
- Secondary IDsM08PBI NKI
- Public TitleImage guided Pre-operative Accelerated partial Breast Irradiation (PAPBI): Defening radiotherapy sensivity.
- Scientific TitleImage guided Pre-operative Accelerated partial Breast Irradiation (PAPBI): Defening radiotherapy sensivity.
- ACRONYMPAPBI
- hypothesisPre-operative accelerated partial breast radiotherapy will be superior compared to conventional radiotherapy for fibrosis and cosmetic outcome, and we think this new treatment will be superior to conventional post-operative whole breast radiotherapy which is used up till now.
- Healt Condition(s) or Problem(s) studiedBreast cancer, Partial breast radiotherapy, Pre-operative
- Inclusion criteriaPatients ≥ 60 years of age with proven adenocarcinoma of the breast presenting with an unifocal lesion on mammogram and MRI (no diffuse microcalcifications), tumor size up till 3.0 cm.
- Exclusion criteria1. Age < 60 year;
2. Multifocal disease;
3. Lobulair carcinoom;
4. pN+.
- mec approval receivedyes
- multicenter trialyes
- randomisedno
- groupParallel
- TypeSingle arm
- Studytypeintervention
- planned startdate 15-jan-2009
- planned closingdate1-dec-2011
- Target number of participants120
- InterventionsThe additional procedures in this study are:
1. Biopsies before radiotherapy;
2. Cytology at day 2 and 12 of radiotherapy;
3. MRI before operation;
4. A Pet scan will be done twice;
5. Also, the sentinel procedure will take place before radiotherapy.
- Primary outcomeTumor response after radiotherapy will histologically be evaluated. Local control will be evaluated during follow-up.

Cosmetic evaluation will take place including digital photographs which will be analyze using computer software as well as questionnaires for the patient and treating physician.
- Secondary outcomemRNA gene expression profiles, miRNA expression profiles and DNA copy number changes associated with response to radiotherapy defined as pathologic response assessed in the lumpectomy 6 weeks after radiotherapy will be identified. 60 Patients will be studied as a test set to identify predictive profiles.

Responders are defined as Complete Respons and >50% Partial Response 6 weeks after radiotherapy. It is estimated, based on literature, that 50% of the patients will be defined responders. 60 Patients will be studied as a test set to identify predictive profiles; 60 patients will be used as a validation set.
- Timepoints1. 60 Patients will be studied as a test set to identify predictive profiles;
2. 60 patients will be used as a validation set.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIES Paula Elkhuizen
- CONTACT for SCIENTIFIC QUERIES Paula Elkhuizen
- Sponsor/Initiator Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI AVL)
- Funding
(Source(s) of Monetary or Material Support)
Dutch Cancer Society
- PublicationsN/A
- Brief summaryPatients with early stage breast cancer are treated with a combination of surgery, radiotherapy and often with systemic therapy. Radiotherapy is part of breast conserving therapy and is known to reduce LR rates in all patients with 60-70% although the absolute benefit differs in different subgroups. So far, no patient groups can be defined in whom radiotherapy would not be necessary. It is estimated that in approximately half of the patients whole breast radiotherapy is not necessary, while in others the tumor might be resistant to radiotherapy. It is likely that tumor cells differ in their response to radiotherapy and thus influence the LR rate after BCT. If it would be possible to predict tumor response to radiotherapy, a more tailored treatment can be advised to individual patients (higher boost dose or primary mastectomy).
- Main changes (audit trail)
- RECORD30-nov-2010 - 15-dec-2010


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl